PPARalpha agonists reduce 11beta-hydroxysteroid dehydrogenase type 1 in the liver

Area of Science:

• Biochemistry
• Endocrinology
• Metabolic Diseases

Background:

• 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) enzyme interconverts cortisone and cortisol.
• Cortisol-cortisone interconversion is crucial for glucose metabolism regulation.
• Peroxisome proliferator-activated receptors (PPAR) are key regulators of glucose and lipid homeostasis.

Purpose of the Study:

• To investigate the effect of PPARalpha agonists on hepatic 11betaHSD1 expression and activity.
• To explore the link between PPARalpha activation, glucocorticoid metabolism, and glucose homeostasis.

Main Methods:

• Chronic treatment of wild-type mice with PPARalpha agonists.
• Assessment of hepatic 11betaHSD1 expression and activity.
• Comparison with PPARalpha knockout mice and short-term treatment groups.

Main Results:

• Chronic PPARalpha agonist treatment significantly downregulated hepatic 11betaHSD1 expression and activity in wild-type mice.
• No significant changes in 11betaHSD1 were observed in PPARalpha knockout mice or after short-term (7h) agonist treatment.
• These results indicate a time-dependent and PPARalpha-dependent regulation of 11betaHSD1.

Conclusions:

• PPARalpha agonists can modulate glucocorticoid metabolism in the liver through the regulation of 11betaHSD1 expression following chronic treatment.
• This modulation of hepatic active glucocorticoid levels by PPARalpha agonists may contribute to their known antidiabetic effects.
• The findings highlight a novel mechanism by which PPARalpha agonists influence glucose metabolism.